Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC.NVLS · Entity 90802 | Director | September 12, 2016 | September 14, 2016 |
| ARRAY BIOPHARMA INCARRY · Entity 155788 | VP, General Counsel | April 01, 2017 | April 06, 2017 |
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | General Counsel | August 12, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALPINE IMMUNE SCIENCES, INC.
Report date September 12, 2016 · Filed September 14, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.77 · Expires 2026-09-12 | Direct | 12,300 |
Reported balance
After 2016-09-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-09-12 · Grant · Acquired 12,300 · Balance 12,300 F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2: The shares shall vest in 12 equal monthly installments commencing on October 12, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F2: The shares shall vest in 12 equal monthly installments commencing on October 12, 2016.
ARRAY BIOPHARMA INC
Report date April 01, 2017 · Filed April 06, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,102 |
Reported balance
After 2017-04-01 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-04-01 · Tax withholding · Disposed 6,370 · Balance 40,102 F1: This amendment to form 4 is being filed to correct number of shares withheld to satisfy the reporting person's tax withholding obligations in connection with the vesting of Restricted Stock Units, and to correct the ending balance previously reported on a form 4 by the reporting person. No other information in such form 4 is being amended. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment to form 4 is being filed to correct number of shares withheld to satisfy the reporting person's tax withholding obligations in connection with the vesting of Restricted Stock Units, and to correct the ending balance previously reported on a form 4 by the reporting person. No other information in such form 4 is being amended.
Edgewise Therapeutics, Inc.
Report date August 12, 2026 · Filed August 17, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2036-08-12 | Direct | 65,000 |
Reported balance
After 2026-08-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-08-12 · Grant · Acquired 65,000 · Balance 65,000 F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2022 Filed Jun 7, 2022 23:03 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 17,150 | $0.71 | $12,176.50 |
DisclosureSEC source: 0001562180-22-004887 · primarydocument.xml · nonDerivative · entry 7 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2022 Filed Jun 7, 2022 23:03 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 973 | $6.61 | $6,426.67 |
DisclosureSEC source: 0001562180-22-004887 · primarydocument.xml · nonDerivative · entry 6 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F5 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.01 to $6.91, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2022 Filed Jun 7, 2022 23:03 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 973 | $1.93 | $1,877.89 |
DisclosureSEC source: 0001562180-22-004887 · primarydocument.xml · nonDerivative · entry 5 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2022 Filed Jun 7, 2022 23:03 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,934 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-22-004887 · primarydocument.xml · derivative · entry 10 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,894 Underlying: Common Stock · 13,934 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| June 06, 2022 Filed Jun 7, 2022 23:03 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 13,934 | $6.03 | $84,084.72 |
DisclosureSEC source: 0001562180-22-004887 · primarydocument.xml · nonDerivative · entry 4 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.18, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 06, 2022 Filed Jun 7, 2022 23:03 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 13,934 | $1.93 | $26,892.62 |
DisclosureSEC source: 0001562180-22-004887 · primarydocument.xml · nonDerivative · entry 3 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 23:03 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,230 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-22-004887 · primarydocument.xml · derivative · entry 9 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,828 Underlying: Common Stock · 15,230 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 23:03 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 15,230 | $6.05 | $92,197.85 |
DisclosureSEC source: 0001562180-22-004887 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 23:03 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 15,230 | $1.93 | $29,393.90 |
DisclosureSEC source: 0001562180-22-004887 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022. F2 · balance_after: Includes 1,438 shares purchased on May 16, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| May 16, 2022 Filed May 18, 2022 21:15 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 10,800 | $7.42 | $80,145.72 |
DisclosureSEC source: 0001562180-22-004201 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $7.11 to $8.05, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 1,438 shares purchased on May 16, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:14 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 15,625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-003665 · primarydocument.xml · derivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 15,625 shares Expires 2025-05-01 F1 · shares: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. F1 · derivative.exercise_date: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 23:50 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,400 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001562180-22-000645 · primarydocument.xml · derivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,322 Underlying: Common Stock · 5,400 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 23:50 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,400 | $0.71 | $3,834.00 |
DisclosureSEC source: 0001562180-22-000645 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 22:51 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,400 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001562180-21-007920 · primarydocument.xml · derivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,722 Underlying: Common Stock · 5,400 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 22:51 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,400 | $0.71 | $3,834.00 |
DisclosureSEC source: 0001562180-21-007920 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,562 shares purchased on November 15, 2021 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:09 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $16.38 | $0.00 |
DisclosureSEC source: 0001562180-21-005462 · primarydocument.xml · derivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-08-17 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 21:41 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 6,718 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-001462 · primarydocument.xml · derivative · entry 3 MOORE JOHN R · CIK 0001191702 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,157 Underlying: Common Stock · 6,718 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares issued on settlement of Restricted Stock Units ("RSUs") granted to the reporting person, of which 2,105 shares were withheld upon vesting to satisfy tax. The grant of these RSUs was previously reported on Table II of a form 4 filed by the reporting person. F4 · derivative.exercise_date: The RSUs vest and will be settled in stock in four equal annual installments beginning April 1, 2017. F5 · balance_after: Consists of unvested RSUs awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs was previously reported on Table II of a form 4 filed by the reporting person. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 21:41 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Tax withholdingCommon Stock | 4,408 | $8.94 | $39,407.52 |
DisclosureSEC source: 0001562180-17-001462 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,064 F3 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person in connection with the vesting of RSUs held by the reporting person. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 21:41 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 6,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-001462 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares issued on settlement of Restricted Stock Units ("RSUs") granted to the reporting person, of which 2,105 shares were withheld upon vesting to satisfy tax. The grant of these RSUs was previously reported on Table II of a form 4 filed by the reporting person. F2 · balance_after: Includes 13,438 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document |
| April 01, 2017 Filed Apr 6, 2017 20:30 UTC Amendment | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Tax withholdingCommon Stock | 6,370 | $8.94 | $56,947.80 |
DisclosureSEC source: 0001562180-17-001484 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,102 F1 · shares: This amendment to form 4 is being filed to correct number of shares withheld to satisfy the reporting person's tax withholding obligations in connection with the vesting of Restricted Stock Units, and to correct the ending balance previously reported on a form 4 by the reporting person. No other information in such form 4 is being amended. Read SEC document |
| December 27, 2016 Filed Dec 29, 2016 17:52 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantStock Option (Right to Buy) · Derivative | 131,250 | $0.00 Strike: $8.79 | $0.00 |
DisclosureSEC source: 0001562180-16-003917 · primarydocument.xml · derivative · entry 2 MOORE JOHN R · CIK 0001191702 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2026-12-27 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on December 16, 2017. Read SEC document |
| December 27, 2016 Filed Dec 29, 2016 17:52 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantRestricted Stock Units · Derivative | 21,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-16-003917 · primarydocument.xml · derivative · entry 1 MOORE JOHN R · CIK 0001191702 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,875 Underlying: Common Stock · 21,875 shares Expires 2020-12-28 F1 · derivative.exercise_date: Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2017. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 20:16 UTC | ALPINE IMMUNE SCIENCES, INC. NVLS · Entity 90802 | GrantStock Option (Right to Buy) · Derivative | 12,300 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001104659-16-144635 · a4.xml · derivative · entry 1 MOORE JOHN R · CIK 0001191702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,300 Underlying: Common Stock · 12,300 shares Expires 2026-09-12 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: The shares shall vest in 12 equal monthly installments commencing on October 12, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.